Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 11/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.37 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.37 |
| ▸ | CDC25B | P30305 | 1/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
| ▸ | PRKCA | P17252 | 1/20 | 0.36 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL771661 | 0.93 | KCNH2 (0.39) | SMN1; SMN2NR1I2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL803957 | 0.92 | KCNH2 (0.38) | SMN1; SMN2NR1I2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL772439 | 0.87 | SMN1; SMN2 (0.39) | PTPN1SMN1; SMN2NR1I2CYP3A4CYP2C9 | |
| SCHEMBL772628 | 0.87 | NR1I2 (0.40) | PTPN1SMN1; SMN2NR1I2CYP3A4CYP2C9 | |
| SCHEMBL773185 | 0.87 | NR1I2 (0.39) | PTPN1SMN1; SMN2NR1I2CYP3A4CYP2C9 | |
| SCHEMBL773732 | 0.86 | NR1I2 (0.41) | SMN1; SMN2NR1I2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL771810 | 0.82 | KCNH2 (0.42) | SMN1; SMN2NR1I2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL12429109 | 0.82 | PTPN1 (0.38) | PTPN1SMN1; SMN2NR1I2CYP3A4CYP2C9 | |
| SCHEMBL772860 | 0.81 | NR1I2 (0.38) | PTPN1SMN1; SMN2NR1I2CYP3A4CYP2C9 | |
| SCHEMBL3780892 | 0.81 | KCNH2 (0.41) | SMN1; SMN2NR1I2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-2206715-A1 | Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor | Japan Tobacco, Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
| EP-1719773-B1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-1719773-A1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2006-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | PTPN1 319/4885SMN1; SMN2 4306/4885NR1I2 1189/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | PTPN1 319/4885SMN1; SMN2 4306/4885NR1I2 1189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.